Poseltinib - Eli Lilly/Hanmi Pharmaceutical

Drug Profile

Poseltinib - Eli Lilly/Hanmi Pharmaceutical

Alternative Names: HM 71224; LY 3337641

Latest Information Update: 04 Nov 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Hanmi Pharmaceutical
  • Developer Eli Lilly; Hanmi Pharmaceutical
  • Class Antirheumatics; Piperazines; Pyrimidines; Small molecules
  • Mechanism of Action Agammaglobulinaemia tyrosine kinase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Rheumatoid arthritis

Most Recent Events

  • 15 Aug 2018 Eli Lilly terminates the phase II RAjuvenate trial for Rheumatoid arthritis in South Africa, Japan, Spain, Germany, Slovakia, Poland, Mexico, South Korea, Italy, Austria, Australia, Puerto Rico, Argentina, USA (PO) (NCT02628028)
  • 24 Jun 2018 Biomarkers information updated
  • 22 May 2018 Phase-II clinical trials ongoing for Rheumatoid arthritis in Argentina, Puerto Rico, Australia, Austria, Italy, South Korea, Mexico, Poland, Slovakia, Germany, Spain, Japan, South Africa, USA (PO) (Hanmi pipeline, May 2018)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top